Arcutis patents expiration
1. Zoryve patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9884050 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US9907788 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US10940142 | ARCUTIS | Inhibition of crystal growth of roflumilast |
Jun, 2037
(13 years from now) | |
| US11129818 | ARCUTIS | Topical roflumilast formulation having improved delivery and plasma half life |
Aug, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Jul 29, 2025 |
Drugs and Companies using ROFLUMILAST ingredient
Market Authorisation Date: 29 July, 2022
Treatment: Topical treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age and older. (1)
Dosage: CREAM;TOPICAL
More Information on Dosage
ZORYVE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic